AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16075692 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate responses to crises
Number of subjects: 0
Study 16075692 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors contributing to crisis resolution and prevention
Number of subjects: 0
Study 12169041 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 7.5mg under fed conditions
Number of subjects: 18
Study 12169041 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 7.5mg under fasted conditions
Number of subjects: 18
Study 10850247 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with AEliteflo
Number of subjects: 14
Study 10850247 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with Bisco Glaze
Number of subjects: 14
Study 10850247 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with Silux Plus
Number of subjects: 14
Study 8784084 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone (Group 1)
Number of subjects: 70
Study 8784084 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg methimazole daily plus sufficient T4 to maintain TSH in the high-normal range (Group 2)
Number of subjects: 70
Study 8784084 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg methimazole daily plus sufficient T4 to suppress TSH to below 0.6 mIU/L (Group 3)
Number of subjects: 70
Study 1473391 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg i.v. under normal condition (PetCO2 5‐5.5kPa)
Number of subjects: 15
Study 1473391 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg i.v. under hyperventilation (PetCO2 3‐3.5kPa)
Number of subjects: 15
Study 6734304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of bacampicillin hydrochloride (400 mg)
Number of subjects: 12
Study 6734304 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of bacampicillin hydrochloride (400 mg)
Number of subjects: 12
Study 30609152 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (continued treatment group)
Number of subjects: 25
Study 30609152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinuation group)
Number of subjects: 25
Study 29812983 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist group
Number of subjects: 43
Study 29812983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 26897490 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) periarticular injection, n = 20
Number of subjects: 38
Study 26897490 — intervention group
Group type: COMPARATOR
Intervention: Standard periarticular injection (ropivacaine, clonidine, Toradol, Epinepherine, saline), n = 18
Number of subjects: 38
Study 24690101 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive palliative care with regular consultations from a specialized palliative care team for patients meeting two or more criteria of the set of indicators.
Number of subjects: 6
Study 24690101 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual care) for all patients in the study.
Number of subjects: 6
Study 21883656 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior partial fundoplication (AF)
Number of subjects: 100
Study 21883656 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (NF)
Number of subjects: 100
Study 20574936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnoreflexogenous birth preparation course
Number of subjects: 101
Study 20574936 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital birth register 2001-2008)
Number of subjects: 101
Study 18271226 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling method of harmonizing spleen-stomach (acupuncture at specific points)
Number of subjects: 130
Study 18271226 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetic therapy with acupuncture at specific points (control group)
Number of subjects: 130
Study 15952402 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg monthly injection) + Calcium (500 mg daily) + Vitamin D (400 U daily)
Number of subjects: 40
Study 15952402 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg daily) + Vitamin D (400 U daily)
Number of subjects: 40
Study 12003578 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 101
Study 10462651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting (Group A)
Number of subjects: 60
Study 10462651 — intervention group
Group type: COMPARATOR
Intervention: Non-lifting (Group B)
Number of subjects: 60
Study 7596123 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine retard 8 mg
Number of subjects: 50
Study 7596123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1486070 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment and 0.1% betamethasone (Betnesol) drops
Number of subjects: 30
Study 1486070 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir ointment and matching placebo
Number of subjects: 30
Study 1486070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 6489764 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-dergocrine mesylate (Hydergine) 1.5 three times daily
Number of subjects: 99
Study 6489764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 30017006 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management (TCM) programme
Number of subjects: 2075
Study 30017006 — intervention group
Group type: COMPARATOR
Intervention: Teaching As Usual (TAU)
Number of subjects: 2075
Study 30132010 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 12
Study 30132010 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 12
Study 30132010 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-controlled electrical stimulation (combined with either active or sham transcranial direct current stimulation)
Number of subjects: 12
Study 27729533 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading intervention focusing on the malleability of reading abilities and praising effort; details on dosage and duration not available.
Number of subjects: 1587
Study 27729533 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading intervention; details on dosage and duration not available.
Number of subjects: 1587
Study 24196263 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) for 10 min
Number of subjects: 40
Study 24196263 — intervention group
Group type: COMPARATOR
Intervention: Internally cooled radiofrequency ablation (RFA) for 12 min
Number of subjects: 40
Study 22012861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg kg(‐1) of corrected body weight (Group SUG)
Number of subjects: 70
Study 22012861 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg kg(‐1) of corrected body weight (Group NEO)
Number of subjects: 70
Study 20682754 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated faces with varying gender dimensions
Number of subjects: 0
Study 20682754 — intervention group
Group type: EXPERIMENTAL
Intervention: Real faces with gendered facial cues
Number of subjects: 0
Study 20682754 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of gendered cues in sexual orientation judgments
Number of subjects: 0
Study 20682754 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments of targets countering stereotypes
Number of subjects: 0
Study 16990498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (H group)
Number of subjects: 18
Study 16990498 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training (Nor group)
Number of subjects: 18
Study 15677779 — intervention group
Group type: EXPERIMENTAL
Intervention: PACCTS (Pro‐Active Call Center Treatment Support)
Number of subjects: 591
Study 15677779 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 591
Study 11865416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (400/100 mg or 400/200 mg twice daily)
Number of subjects: 70
Study 11865416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir plus Nevirapine (200 mg 2x/day) and nucleoside reverse-transcriptase inhibitors
Number of subjects: 70
Study 11865416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir treatment
Number of subjects: 70
Study 10541953 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 9
Study 7874950 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus NIPSV (n = 21)
Number of subjects: 41
Study 7874950 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n = 20)
Number of subjects: 41
Study 7874950 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus NIPSV (n = 17, subgroup with PaCO2 > 45 mm Hg)
Number of subjects: 41
Study 7874950 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n = 17, subgroup with PaCO2 > 45 mm Hg)
Number of subjects: 41
Study 2211567 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5-10 mg t.i.d. for 6 weeks
Number of subjects: 230
Study 2211567 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam 10-20 mg t.i.d. for 6 weeks
Number of subjects: 230
Study 2211567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 230
Study 322325 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide (S 852)
Number of subjects: 12
Study 322325 — intervention group
Group type: EXPERIMENTAL
Intervention: glibenese
Number of subjects: 12
Study 30011020 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokeFree Baby app (v1)
Number of subjects: 565
Study 28431870 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Mannitol (MT)
Number of subjects: 2
Study 28431870 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline (HTS)
Number of subjects: 2
Study 26592226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Abrasion Technique (FAT)
Number of subjects: 20
Study 26592226 — intervention group
Group type: COMPARATOR
Intervention: Foam Rolling (FR)
Number of subjects: 20
Study 23905374 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolate (200 mg/day) with routine Western medical treatment
Number of subjects: 83
Study 23905374 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medical treatment (Control)
Number of subjects: 83
Study 20659908 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH)
Number of subjects: 40
Study 20659908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 40
Study 20659908 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 40
Study 19156019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by Speech and Language Pathologists/Therapists targeting CAS
Number of subjects: 31
Study 19156019 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 31
Study 16542205 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 18
Study 16542205 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (100 mg daily)
Number of subjects: 18
Study 16542205 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1*1b allele carriers
Number of subjects: 18
Study 15264506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (GC)
Number of subjects: 32
Study 15264506 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (GR)
Number of subjects: 32
Study 11522675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (blood glucose reduced to 54 mg/dl)
Number of subjects: 26
Study 11522675 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic clamp (blood glucose maintained near 100 mg/dl)
Number of subjects: 26
Study 9233903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone (MES) 100 mg/d
Number of subjects: 55
Study 9233903 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 160 mg/d
Number of subjects: 55
Study 9233903 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 250 mg i.m./21 days
Number of subjects: 55
Study 9233903 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg crystalline testosterone (TPEL) subcutaneously implanted
Number of subjects: 55
Study 8502509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin (0.3 mg/kg per dose)
Number of subjects: 206
Study 3102211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group (TG) with CDP of 6 cm water pressure applied at birth by the nasopharyngeal route.
Number of subjects: 82
Study 3102211 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with CDP applied when indicated for established criteria (pO2 less than 50 mmHg in FiO2 greater than 0.5).
Number of subjects: 82
Study 3102211 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with CDP applied when indicated for established criteria.
Number of subjects: 82
Study 3102211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG).
Number of subjects: 82
Study 29938412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 2% (Group A)
Number of subjects: 710
Study 29938412 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group B)
Number of subjects: 710
Study 27619831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockwood Instability programme
Number of subjects: 0
Study 27619831 — intervention group
Group type: COMPARATOR
Intervention: Watson MDI programme
Number of subjects: 0
Study 26238225 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 26238225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23619815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanoplasty type I using pure perichondrium
Number of subjects: 80
Study 20565229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (Spiriva)
Number of subjects: 19000
Study 20565229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19000
Study 18700624 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel (10 ml/kg intravenously over 10‐15 minutes)
Number of subjects: 120
Study 18700624 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection ephedrine (0.2 mg/kg iv)
Number of subjects: 120
Study 18700624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no study medication)
Number of subjects: 120
Study 15696985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate foam 1% (CF)
Number of subjects: 0
Study 15696985 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate topical gel 1% (CG)
Number of subjects: 0
Study 12601094 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 102
Study 12601094 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 102
Study 12601094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 102
Study 12601094 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 10548211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (20 units/kg bolus, 10 units/kg/hr infusion)
Number of subjects: 57
Study 10548211 — intervention group
Group type: COMPARATOR
Intervention: Heparin (2000-5000 units bolus, 10 units/kg/hr infusion, titrated to 70-80 secs aPTT)
Number of subjects: 57
Study 10548211 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 57
Study 10548211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 57
Study 8522709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 36
Study 8522709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 36
Study 1841043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg
Number of subjects: 78
Study 1841043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 78
Study 6301320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus immune globulin administered before and for 11 weeks after transplantation
Number of subjects: 36
Study 6301320 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte transfusions from seropositive donors
Number of subjects: 36
Study 31934788 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Early Program (StEP) intervention with prenatal/postpartum individual nutrition counseling and nutrition and parenting support groups
Number of subjects: 533
Study 31934788 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Early Program (StEP) intervention
Number of subjects: 533
Study 31664156 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered acidic saline solution (pH 5.2)
Number of subjects: 14
Study 31664156 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (pH 6)
Number of subjects: 14
Study 29063837 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 134
Study 27095804 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide
Number of subjects: 0
Study 27095804 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab
Number of subjects: 0
Study 24560062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine added to standard-of-care (SoC) treatment
Number of subjects: 0
Study 24560062 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) treatment alone
Number of subjects: 0
Study 24560062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine added to SoC
Number of subjects: 0
Study 22834720 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative care (IV epidural preload volume of <500 mLs continuing at an hourly rate of 75-100 mL/h)
Number of subjects: 200
Study 22834720 — intervention group
Group type: COMPARATOR
Intervention: Usual care (epidural preload volume of ≥500 mLs and an hourly rate >125 mL/h)
Number of subjects: 200
Study 22834720 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 22834720 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative care
Number of subjects: 200
Study 22834720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 19273551 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant group (1 g l-ascorbic acid, 400 IU alpha-tocopherol acetate, 600 mg alpha-lipoic acid in four divided doses)
Number of subjects: 83
Study 19273551 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 83
Study 19273551 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant group
Number of subjects: 83
Study 18558509 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 30
Study 18558509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16238973 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy combined with HDR brachytherapy (46 Gy external irradiation and 2 HDR fractions of 1150 cGy each)
Number of subjects: 100
Study 12383043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium 10mg + aspirin 975mg
Number of subjects: 0
Study 12383043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium 10mg + piroxicam 20mg
Number of subjects: 0
Study 12383043 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux sodium 10mg
Number of subjects: 0
Study 12383043 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20mg
Number of subjects: 0
Study 12383043 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20mg + fondaparinux sodium 10mg
Number of subjects: 0
Study 10369196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0
Study 10369196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0
Study 10369196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 0
Study 10369196 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor
Number of subjects: 0
Study 10369196 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, dipyridamole, warfarin
Number of subjects: 0
Study 10369196 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 0
Study 8537694 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (L) 75 mg/day
Number of subjects: 30
Study 8537694 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (M) 30 mg/day
Number of subjects: 30
Study 2406218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin 0.1% twice daily during the holiday
Number of subjects: 39
Study 2406218 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol therapy restored after holiday
Number of subjects: 39
Study 2406218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin-treated group (60 days treatment)
Number of subjects: 39
Study 6996779 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 307
Study 6996779 — intervention group
Group type: COMPARATOR
Intervention: Medical units
Number of subjects: 307
Study 30651117 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Mile Club walking/running program
Number of subjects: 13
Study 30651117 — intervention group
Group type: COMPARATOR
Intervention: CHALK/Just Move classroom activity break PA program
Number of subjects: 13
Study 28241070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisensory‐DBM with scented cream
Number of subjects: 93
Study 28241070 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory‐DBM with scented cream associated with audiovisual material
Number of subjects: 93
Study 28241070 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 93
Study 24604029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% taurolidine lock (group A)
Number of subjects: 30
Study 24604029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.35% taurolidine + citrate lock (group B)
Number of subjects: 30
Study 24604029 — intervention group
Group type: COMPARATOR
Intervention: Control - saline flush (group C)
Number of subjects: 30